Jul 2
|
mAbxience Announces European Commission Approval of Denosumab Biosimilars
|
Jul 2
|
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
|
Jul 1
|
Trading Rotation Kicks Off 2nd Half of 2025
|
Jul 1
|
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint
|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
Jun 30
|
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
|
Jun 30
|
2 Dividend Stocks to Buy on the Dip and Hold Forever
|
Jun 28
|
Jim Cramer Says That Amgen’s Stock “Did Not Deserve to Get Hit This Hard”
|
Jun 27
|
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
|
Jun 27
|
Here's Why Amgen (AMGN) is a Strong Growth Stock
|
Jun 27
|
Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations
|
Jun 26
|
5 Insightful Analyst Questions From Amgen’s Q1 Earnings Call
|
Jun 25
|
Amgen (AMGN) Stock Moves 1.03%: What You Should Know
|
Jun 25
|
Jim Cramer on Keurig Dr Pepper: “I Don’t Want to Touch That One”
|
Jun 25
|
In the wake of Amgen Inc.'s (NASDAQ:AMGN) latest US$6.5b market cap drop, institutional owners may be forced to take severe actions
|
Jun 15
|
Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial
|
Jun 13
|
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
|
Jun 13
|
Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
|
Jun 13
|
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
|
Jun 12
|
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
|